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Abstract
Objectives Levodopa–Carbidopa Intrajejunal gel (LCIG) infusion is an effective intervention for people with advanced 
Parkinson’s disease (PD). Although age may not be a limiting factor for LCIG implant, no data are available on late elderly 
PD (LE-PD) subjects. In this cross-sectional, we aimed to demonstrate if older age may impact on quality of life (QoL), 
motor and non-motor symptoms severity, and profile of side effects in PD treated with LCIG.
Methods Out of 512 PD subjects treated with LCIG at 9 Italian PD centers, we selected 25 LE-PD defined as age ≥ 80 years 
at last follow-up who were available to attend the study visit. Twenty-five PD patients (Control-PD, defined as age < 75 years 
at last follow-up) matched to LE-PD by disease and LCIG duration served as control group. The following motor and non-
motor variables were ascertained: quality of life (PDQ-8), time spent in ON, wearing-off Questionnaire, Unified PD Rating 
Scale, freezing of gait questionnaire, Parkinson’s disease sleep scale-2, Non Motor Symptoms Scale (NMSS), and MOCA.
Results No statistically significant differences were found between LE-PD and Control-PD on PDQ-8 and several motor 
and non-motor variables. LE-PD had less frequent and milder impulsive–compulsive behaviors and milder dyskinesia. At 
multivariable regression, worse quality of life was associated with UPDRS-III and NMSS scores but not to age at study 
visit and age at LICG implant. Rate of adverse effects was similar in both groups. Drop-out rate calculated in the whole PD 
cohort was comparable between the two groups.
Conclusion Our data provide evidence that valuable LCIG infusion might be achieved in late elderly PD.
Keywords Parkinson’s disease · Motor fluctuations · Dyskinesia · Levodopa–carbidopa intestinal gel (LCIG) · Old age · 
Quality of life
Introduction
Advanced Parkinson’s disease (PD) encompasses a wide 
spectrum of motor and non-motor symptoms which ulti-
mately affect the choice of treatment aimed to improve 
quality of life. The presence of disabling motor fluctuations 
and/or dyskinesia, despite adjustment of oral medication, 
represents an indication for device-aided treatments, such 
as Deep Brain Stimulation (DBS), continuous subcutane-
ous apomorphine (CSAI), and levodopa–carbidopa intestinal 
gel (LCIG) infusion. Accordingly, best outcomes occur in 
younger PD subjects in whom axial symptoms, such as gait 
and balance disturbances, are not prominent [14, 24]. Given 
the increased incidence of PD in the elderly population 
and prolonged survival as a consequence of dopaminergic 
replacement treatment [16], it is expected that a proportion 
of patients with long disease duration, motor complications, 
and relatively preserved cognitive features might be suitable 
for device-aided therapies also in very old age. Older popu-
lation is growing in industrialized countries and outcomes 
of different pharmacological interventions from cohorts of 
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“late elderly” (LE) subjects are increasingly reported, at least 
for dementia [10].
Older age is a limiting factor for DBS eligibility [2, 15], 
as in the elderly population the effect on quality of life is 
not significant [6, 26] and age is associated with higher risk 
of post-operative complications [21]. No data have been 
reported so far about safety of CSAI and LCIG in elderly 
cohorts (i.e., ≥ 80 years) and their impact on quality of life, 
despite a recent Delphi consensus of movement disorders 
experts have suggested that age may not be a limiting factor 
[2]. A post hoc analysis of the GLORIA registry reported 
improvement of quality of life (QoL) in younger and older 
patients under LCIG, but cut-off was set at age 65 and evalu-
ation of non-motor symptoms was not reported [1]. One ret-
rospective study conducted in a CSAI cohort showed that 
efficacy, rated by clinical global impression, was comparable 
in younger and older PD patients [17]. Yet, a few studies 
suggested that older age might be a factor leading to discon-
tinuation of infusion therapies [3, 17, 19, 25]. Accordingly, 
a higher risk of dropout from LCIG infusion, especially in 
the first year of treatment, was found in patients older than 
70 years due to surgery, device, and infusion-related com-
plications [3]. For CSAI, factors leading to discontinuation 
in older patients were side effects, mainly neuropsychiatric 
[25], worsening of cognition, and lack of control of dyski-
nesia [17].
In the present study, we tested the hypothesis whether 
older age may impact on QoL, motor and non-motor symp-
toms severity, and profile of side effects in PD subjects 
treated with LCIG. We predicted that late elderly Parkinson’s 
disease patients implanted with LCIG because of disabling 
motor complications will have similar QoL to younger PD 
subjects. To this aim, we designed a cross-sectional study 
comparing LE-PD patients (age ≥ 80 years) to a control PD 
group (age < 75 years) matched by disease duration and time 
receiving LCIG.
Methods
This was a cross-sectional study with a retrospective analysis 
of adverse effects and quality-of-life pre-LCIG. PD patients 
who underwent LCIG infusion for at least 6 months were 
enrolled from nine Italian tertiary referral centers for PD. 
Clinical evaluations were performed at the time of study 
visit which corresponded to the latest follow-up after LCIG.
Inclusion criteria for LCIG at the time of implant were: a 
diagnosis of PD according to MDS diagnostic criteria [18]; 
presence of severe motor fluctuations and/or dyskinesia 
despite best medical treatment; absence of severe psycho-
sis or severe hallucinations; absence of systemic diseases 
which may interfere with the device and LCIG therapy; 
absence of dementia (by DSM-IV criteria). We defined 
subjects aged ≥ 80 years as “late elderly PD” (LE-PD) and 
subjects aged < 75 years as “Control-PD”. This cut-off was 
chosen based on previous studies in elderly cohorts [10] 
which defined 75 years as the cut-off to distinguish mid-
dle elderly (< 75 years) from late elderly (> 75 years). We 
raised the threshold for late elderly to ≥ 80 years to further 
distinguish the two cohorts. From the whole LCIG cohort 
actively followed up in each center), we selected LE-PD 
patients available to attend study visits. Subsequently, we 
identified Control-PD patients matched by disease duration 
and LCIG duration.
Institutional ethics approval was obtained in the Coordi-
nator Centre (AOU Brotzu, Cagliari, Pr. PG 2017/17817) 
and approved by the ethical Committees of each participat-
ing centers. Each participant provided written informed con-
sent before study participation.
Demographical and clinical variables
For each subject, the following demographic and clinical 
data were collected at the time of study entry: age, gender, 
education level, weight, age at disease onset, disease dura-
tion, most affected side, LCIG duration, and all type and 
number of current comorbidities (at the time of study inclu-
sion). Charlson Comorbidity Index (CCI) was also employed 
to categorize comorbidities.
Quality of life was assessed by means of the Parkinson’s 
Disease Questionnaire-8 (PDQ-8) summary index. For 
motor symptoms, we employed: Unified Parkinson’s Disease 
Rating Scale parts II, III (in the ON state) and IV, respec-
tively, for disease severity and complication of therapy; Rush 
Dyskinesia rating scale; Hoehn–Yahr stage; freezing of gait 
questionnaire (FOG-Q); time spent in ON (hours/day, based 
on therapy’s diary). PDQ-8 and time spent in ON (hours/
day) were also retrospectively retrieved at the time before 
having LCGI (as per LCGI protocol in the centers participat-
ing in this study).
Motor and non-motor fluctuations were screened by 
means of the 19-items Wearing Off Questionnaire (WOQ-
19). Non-motor symptoms were assessed with Non-Motor 
Symptoms Scale (NMSS). Parkinson’s Disease Sleep scale-
II (PDSS-II) and Epworth Sleepiness scale (EDS) were, 
respectively, employed to rate sleep and excessive daytime 
sleepiness. Overall cognitive function was tested by means 
of the Montreal Cognitive Assessment (MOCA). For impul-
sive–compulsive behavior (ICB) diagnosis, we employed 
a semi-structured interview based on diagnostic criteria 
for pathologic gambling, compulsive buying, compulsive 
sexual behavior, binge eating, punding, and compulsive 
use of dopaminergic therapy. In addition, the Question-
naire for Impulsive–Compulsive Disorders in Parkinson’s 
Disease–Rating Scale (QUIP-RS) was employed. Total and 
impulse control disorder (ICD) score were calculated [28]. 
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Questionnaires from patients with dementia were filled by 
their caregivers.
Information about PD medications at the time of study 
visit was collected and levodopa equivalent daily dose 
(LEDD) and dopamine-agonist equivalent dose (D-Ag 
LEDD) were calculated [27]. LEDD and D-Ag LEDD 
before LCIG were also retrospectively retrieved from medi-
cal records review. Infusion parameters were also recorded, 
including morning (ml) and infusion (ml/hour) dose, bolus 
dose (ml), and number of bolus doses per day.
Adverse effects
We collected surgery-related, device-related, and LCGI 
related adverse effects, since implant and up to latest follow-
up at study visit. Surgery and device-related complications 
included stoma infections and granulomatosis, abdominal 
pain, incision site erythema, complications of device inser-
tion, post-operative delirium, peritonitis, duodenal ulcer, and 
failure of the infusion system. Tube-related adverse effects 
included dislocation, coiling, kinking, and occlusion of the 
intestinal tube. Therapy-related side effects included hallu-
cinations, polyneuropathy (graded as mild, moderate, severe 
based on nerve conduction studies and electromyography), 
delirium, weight loss, taste impairment, and presence of 
moderate/severe dyskinesia. Dyskinesia were defined as 
moderate/severe if item 33 of UPDRS-IV was ≥ 2. For each 
of the adverse effects, the number of events over all follow-
up was calculated.
Drop‑out rate calculation in the whole LCIG cohort
Analysis of the drop-out rate was performed in the whole 
LCIG population followed-up at each participating center to 
verify whether LE-PD subjects included in the studies might 
be representative of a general LE-PD population treated with 
LCIG.
Statistical methods
After checking for normal distribution of the variables by 
Kolmogorov–Smirnov test, groups’ comparisons were per-
formed by either t test or Mann–Whitney for continuous 
variables and Chi-square or Fisher’s exact test for categori-
cal data. For total and D-Ag LEDD, PDQ-8, time in ON 
analysis, we also performed repeated-measure ANOVA 
(R-ANOVA) with “time” (two levels: pre-LCGI, post-
LCGI) as within-subjects factor and “group” (two levels: 
LE-PD, Control-PD) as between-subjects factor. Conditional 
on significant F values, we performed post hoc pair-wise 
comparisons by t test in each group.
QUIP-RS and PDQ-8 at last follow-up after LCIG were 
employed in univariable linear logistic regression analysis 
to explore their relationship with demographic and clinical 
variables. Parameters that were significantly associated with 
the outcome in the univariable analyses were then included 
in a multivariable model. Univariable binary logistic regres-
sion analysis was also employed to explore the association 
between presence of ICB and demographic and clinical 
variables.
Significance level was set at p < 0.05. Statistical analysis 
was performed with SPSS Statistics, version 25. Data are 
shown as mean and standard deviation (SD).
Results
Out of 512 PD subjects implanted with LCIG, we enrolled 
25 patients LE-PD to whom 25 Control-PD patients were 
matched. As per study inclusion criteria, the two groups 
were matched by disease duration and LCIG duration and 
differ by age at study entry (Table 1). The number of patients 
with comorbidities was higher in LE-PD compared to Con-
trol-PD. Mean duration of LCIG treatment was approxi-
mately 5 years in both groups. Daily LCIG dose and morn-
ing LCIG dose did not differ between groups. No differences 
were found in education level, whereas there was a trend 
for MOCA to be lower in LE-PD. At the time of evalua-
tion, 5 subjects satisfied DSM-IV criteria for dementia (n = 3 
LE-PD, n = 2 Control-PD).
Total LEDD and D-Ag LEDD before LCIG were sig-
nificantly lower in LE-PD. LCIG was associated with a sig-
nificant improvement of quality of life, prolongation of time 
spent in ON, and a similar decrease of D-Ag after LCIG in 
both groups compared to baseline (Fig. 1).
With respect to motor and non-motor variables, we did 
not find any significant difference between LE-PD and Con-
trol-PD, except for dyskinesias which were more pronounced 
in Control-PD (p = 0.0477) (Table 1).
ICB was more frequent in Control-PD (N = 14) than 
in LE-PD (N = 6) (p = 0.04). Mean number of ICB per 
patient was comparable (LE-PD = 1.5 ± 0.54; Control-
PD = 1.71 ± 0.91). Figure 2a shows distribution of specific 
ICBs in each group. Binge eating (N = 6) and dopaminergic 
medication abuse were the most frequent ICB in Control-PD 
(N = 5). Total QUIP-RS score and ICD score of QUIP-RS 
(calculated in subjects diagnosed with ICB) were higher in 
Control-PD than LE-PD (Fig. 2b).
Regression analysis
PDQ8 after LCIG was associated with UPDRS-II, 
UPDRS-III, and NMSS but not with age at study visit and 
age at implant by univariable linear regression analysis 
 Journal of Neurology
1 3
(supplementary Table 1). At the multivariable linear analy-
sis, only UPDRS-III and NMSS significantly predicted 
PDQ-8 (Table  2). Using the enter method UPDRS-II, 
UPDRS-III and NMSS explained significant amount 
of the variance in the value of PDQ-8 (F(3,45) = 7.19, 
p =  < 0.0001, R2 = 0.32, R2 Adjusted = 0.28).
Univariable linear regression analysis with Rush Dyski-
nesia Rating Scale as dependent variable showed that only 
age at onset was a significant regressor (B = − 0.154; 95% 
CI (− 0.293, − 0.015); p = 0.03).
Univariable binary logistic regression showed that 
diagnosis of ICB was associated with Control-PD group 
(p = 0.024), D-Ag LEDD post-LCIG (p = 0.004), and it was 
negatively associated with Hoehn–Yahr stage (p = 0.023) 
and NMSS (p = 0.01). At multivariable level, Control-PD 
group (p = 0.026) and NMSS (p = 0.022) were the only sig-
nificant regressors for a diagnosis of ICB (Table 2). The 
four independent variables (Group, D-Ag LEDD, HY, and 
NMSS) in the logistic model together account for 31% 
the explanation for the diagnosis of ICB (Cox & Snell R 
Square = 0.31). Univariable linear regression showed that 
QUIP-RS score was inversely associated with age, age at 
onset, Hoehn–Yahr stage, and Control-PD group (Supple-
mentary Table 2). However, at the multivariable analysis, 
only group predicted the severity of QUIP-RS, confirming 
that Control-PD was associated with more severe ICB. Age 
at onset, group, age, and H&Y explained significant amount 
of the variance in the value of QUIP-RS (F(4,45) = 3.3, 
p = 0.01, R2 = 0.22, R2Adjusted = 0.16).
Adverse effects
Frequency of adverse effects was comparable between the 
two groups (Table 3). In general, patients experienced less 
than 5 adverse events from implant to last follow-up (Sup-
plementary Fig. 1). Incision site erythema or granulomato-
sis, tube dislocation, weight loss, hallucinations, and moder-
ate/severe dyskinesia were the adverse effects experienced 
more commonly. Life-time frequency of surgery and device-
related complications were comparable among LE-PD 
(16/25) and Control-PD (19/25) (p = 0.54). Frequency of 
adverse effects did not differ across centers (p < 0.05).
Table 1  Demographical and 
Clinical data in Late Elderly 
(LE) and Control Parkinson’s 
Disease subjects treated 
with Levodopa–Carbidopa 
Intrajejunal gel (LCIG) infusion
FOG-Q freezing of gait questionnaire, EDS Epworth Sleepiness scale, HY Hoehn–Yahr stage, L Levodopa–
Carbidopa intestinal gel infusion, MOCA Montreal Cognitive Assessment, NMSS Non-Motor Symptoms 
Scale, PDSS-2 Parkinson’s Disease Sleep scale-II, QUIP-RS Questionnaire for Impulsive–Compulsive Dis-
orders in Parkinson’s Disease–Rating Scale, RDRS Rush Dyskinesia rating scale, UPDRS Unified Parkin-
son’s Disease Rating Scale, WOQ-19 Wearing Off Questionnaire 19 items
a QUIP-RS calculated on LE-PD (n = 6) and Control-PD (n = 14) with impulsive–compulsive behavior
*Significant values are bolded
LE-PD
mean ± SD (range)
Control-PD
mean ± SD (range)
p value
Age (years) 81.48 ± 1.73 (80–85) 69.20 ± 5.45 (51–74)  < 0.0001*
Education (years) 8.76 ± 4.05 (3–18) 8.8 ± 4.57 (5–18) 0.945
Disease duration (years) 21.28 ± 7.93 (10–51) 21.28 ± 5.97 (13–38) 0.409
Weight (kg) 61.56 ± 13.41 (33–95) 65.48 ± 17.24 (40–120) 0.409
LCIG duration (months) 59.28 ± 41.62 (4–133) 60.08 ± 37.42 (6–146) 0.846
LCIG dose (ml/day) 45.098 ± 13.15 (21–73.2) 52.336 ± 18.96 (20.4–82.1) 0.148
Morning dose (ml) 4.608 ± 2.72 (0–10.5) 5.188 ± 2.69 (0–10.5) 0.341
UPDRS-II 24.6 ± 9.18 (9–42) 20.36 ± 8.91 (5–39) 0.112
UPDRS-III 39.833 ± 13.61 (21–74) 33.08 ± 14.28 (11–65) 0.107
UPDRS-IV 6.8 ± 3.74 (1–14) 8.92 ± 6.01 (4–34) 0.157
HY 3.74 ± 0.98 (2–5) 3.18 ± 0.97 (1.5–5) 0.062
RDRS 6.04 ± 4.07 (0–12) 9 ± 5.21 (0–18) 0.047*
WOQ-19 total 7.44 ± 5.01 (0–17) 7.44 ± 4.22 (0–20) 0.977
WOQ-19 motor 4.92 ± 3.05 (0–11) 5.08 ± 2.41 (0–10) 0.961
WOQ-19 non-motor 2.88 ± 3.55 (0–15) 2.36 ± 2.50 (0–10) 0.861
NMSS 78.72 ± 46.47 (19–201) 81.64 ± 45.16 (17–188) 0.749
QUIP-RSa 7.50 ± 3.62 (3–12) 15.07 ± 10.08 (5–40) 0.05*
FOG-Q 14.083 ± 6.83 (3–26) 13.84 ± 6.01 (3–24) 0.936
PDSS-2 9.924 ± 1.98 (4–39) 18 ± 11.73 (2–49) 0.594
EDS 5.8 ± 5.33 (0–20) 6.48 ± 5.3 (0–19) 0.449
MOCA 17.52 ± 7.2 (2–28) 20.84 ± 6.58 (2–29) 0.060
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Drop‑out rate in the whole LCIG cohort
We retrospectively compared the number of subjects who 
dropped out from LCIG in Control-PD and LE-PD. Out of 
506 PD patients with available clinical data until last follow-
up (n = 6 were lost to follow-up), there were 111 drop-outs 
(21.75%) and 80 deaths (15.6%) (LE-PD = 47/191, 24.6%, 
Control-PD = 33/315, 10.4%, p = 0.00002). Drop-outs were 
more frequent in Control-PD (82/315, 26.0%) compared to 
LE-PD (29/191, 15.1%, (p = 0.038). There was a significant 
difference in the rate of drop-outs across participating cent-
ers (p < 0.0001; range of drop-out rate: 6–50%). Duration 
of LCIG treatment at drop-out was comparable in LE-PD 
(1.8 ± 1.5 years) and Control-PD (2.8 ± 2.2 years) (p = 0.07). 
Polyneuropathy and lack of compliance with LCIG man-
agement were the most frequent causes of drop-out in 
Control-PD, whereas in LE-PD device-related adverse 
events, lack of benefit and dementia were the most frequent 
causes (Supplementary Fig. 2).
Discussion
Despite strong evidence of efficacy of LCIG and no 
age limit recommendation for this treatment [2], stud-
ies reporting data on subjects older than 80 are lacking. 
Older patients with advanced PD are often not informed 
on the available advanced therapies, including LCIG, or 
are denied the screening for advanced therapies because of 
older age [12]. PD without dementia calculated on Janu-
ary 1, 2006 in Olmsted County had a prevalence of 1.39% 
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Fig. 1  Dopaminergic medications, quality of life, and time in “on” in 
LE-PD and Control-PD. Total and Dopamine-agonists (D-Ag) Levo-
dopa Equivalent Daily Dose (LEDD) (a, b), PDQ-8 summary index 
(SI) and time spent in ON (c, d) before and after Levodopa–Carbi-
dopa Intrajejunal Gel Infusion (LCIG) in “Late elderly” Parkinson’s 
disease (LE-PD) and Control-PD. After LCIG, a significant decrease 
of D-Ag LEDD and PDQ-8 and a significant increase of time spent in 
ON were achieved, without differences between LE-PD and Control-
PD
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47.6% of subjects with PD in that age limit, respectively, 
in men and women [22]. Based on these data, it could be 
estimated that an increasing number of people with PD 
aged > 80 will be in an advanced stage of the disease with-
out dementia and might benefit from device-aided therapy.
Our data provide evidence that both age at last follow-
up and age at implant do not impact on quality of life and 
the severity of a wide spectrum of motor and non-motor 
symptoms in PD treated with LCIG at a mean follow-
up time of 5 years. Indeed, UPDRS-III and NMSS were 
the only factors associated to worst quality of life under 
LCIG treatment. More importantly, profile of side effects 
of LCIG infusion was comparable across age groups.
These results should be evaluated, considering that our 
LE-PD cohort is a specific population of older PD subjects 
who satisfied selection criteria for LCIG and in whom the 
number of accumulated deficits expected for that age is 
lower and contribute to less frailty and success of such 
therapy [11]. In our study, both LE-PD and Control-PD 
had mean disease duration of 21 years. This implies that 
in LE-PD, the disease has started in the early old age and 
progressed to develop disabling motor complications in a 
later old age. Whereas response to oral Levodopa has been 
assessed for PD patients in late stage [8], studies assessing 
LE-PD with long disease duration who still have promi-
nent response to Levodopa with fluctuations and dyskine-
sia are lacking. This is a fundamental issue to clarify, as 
this population could still benefit from infusion therapies, 
if patients met the inclusion criteria. In younger patients 
with disease onset before age 50 and a disease duration of 
up to 30 years, despite worsening of axial and cognitive 
symptoms, response to oral levodopa and STN DBS has 
Fig. 2  Impulsive compulsive 
behaviors in LCIG: effect of 
age. Distribution of different 
types of impulsive–compul-
sive behaviors (ICB) in “Late 
elderly” Parkinson’s disease 
(LE-PD) and Control-PD (a). 
QUIP-RS total score and ICD 
score were significantly higher 
in LE-PD compared to Control-
PD (b). *Mann–Whitney U test
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been proved [13]. Here, we showed a similar pattern for 
those subjects whose disease onset occurred at younger 
age or earlier elderly age and who slowly progressed to 
have severe motor fluctuations in late elderly age. Despite 
similar scores of PDQ-8 and duration of ON time before 
LCIG, LE-PD were treated with significant less dopamin-
ergic medications before LCIG. This might reflect the 
vulnerability of this age group for psychiatric side effects 
and the use of lower doses of dopaminergic medication to 
prevent them [5]. At this regard, the decrease of dopamine 
agonists made possible by LCIG is an opportunity for this 
age group to improve their motor status without producing 
adverse psychiatric side effects.
One of the major issues with LCIG therapy is the rela-
tively high frequency of device-related and infusion-related 
complications, likely determining more frequent drop-outs in 
patients older than 70 [3]. Our data showed a similar rate for 
surgery, device, and infusion-related side effects in LE-PD 
and Control-PD over a long follow-up time. The majority 
of the events were mild and only 20% and 32% of subjects 
with, respectively, LE-PD and Control-PD experienced more 
than 5 events since the implant of LCIG. Nevertheless, the 
high rate of tube dislocation, coiling, kinking, and occlusion 
in our study cohort support the view that these side effects 
are often manageable, especially when a multidisciplinary 
team is involved [23], and do not lead to discontinuation. 
Also, we reported less frequent drop-outs in LE-PD, with 
number of deaths being higher in this group, as expected. 
These data further support the feasibility and management 
of LCIG in late elderly.
Another novel data of our study are that under LCIG 
treatment, LE-PD had less frequent and severe ICB and less 
severe dyskinesia, despite comparable frequency of patients 
Table 2  Multivariable regression analyses with PDQ8, QUIP-RS, and 
ICB diagnosis as dependent variables
CI confidence interval, D-Ag dopamine agonists, HY Hoehn–Yahr 
stage, ICB impulsive–compulsive behaviors, LB lower bound, LCIG 
Levodopa–Carbidopa intestinal gel infusion, LEDD levodopa equiv-
alent daily dose, NMSS Non-Motor Symptoms Scale, UB = upper 
bound, UPDRS Unified Parkinson’s Disease Rating Scale
*Significant values are bolded
B 95% CI–LB 95% CI–UB p Value
Multivariable regression with PDQ8 after LCIG as dependent vari-
able
UPDRS-II − 0.474 − 1.185 0.236 0.185
UPDRS-III 0.581 0.124 1.038 0.014*
NMSS 0.135 0.035 0.235 0.009*
Multivariable binary regression with ICB diagnosis as dependent 
variable
Group 1.747 0.037 0.813 0.026*
D-Ag LEDD 0.007 0.996 1.017 0.215
HY − 0.09 0.391 2.135 0.836
NMSS − 0.027 0.951 0.996 0.022*
Multivariable linear regression with QUIP-RS as dependent vari-
able
Age at onset − 0.138 − 0.444 0.169 0.37
Group − 8.533 − 16.703 − 0.364 0.041*
Age 0.362 − 0.275 0.999 0.258
HY − 2.191 − 4.648 0.266 0.079
Table 3  Adverse Reactions 
(ADR) in Late Elderly (LE) and 
Control Parkinson’s Disease 
subjects treated with Levodopa–
Carbidopa Intrajejunal gel 
infusion
LE-PD (Y/N) Control-PD 
(Y/N)
p value
ADR (> 5 events per patient) 5/20 8/17 0.5
Stoma infection 3/22 7/18 0.289
Abdominal pain 0/25 0/25  > 0.9999
Incision site erythema or granulomatosis 10/15 12/13 0.7761
Complications of device insertion 1/24 2/23  > 0.9999
Peritonitis 0/25 0/25  > 0.9999
Duodenal ulcer 0/25 1/24  > 0.9999
Failure of the infusion system 2/23 5/20 0.4174
Tube dislocation 10/15 6/19 0.3635
Tube coiling, kinking and occlusion 9/16 10/15  > 0.9999
Unintentional removal of tube by the patient 1/24 6/19 0.0983
Hallucinations 7/18 6/19  > 0.9999
Delusions 3/22 3/22  > 0.9999
Polyneuropathy 8/17 7/18  > 0.9999
Delirium 3/22 3/22  > 0.9999
Weight loss 12/13 12/13  > 0.9999
Taste impairment 0/25 2/23 0.4898
Moderate/severe dyskinesia 9/16 11/14 0.7733
 Journal of Neurology
1 3
perceived disabling dyskinesia. The only predictor of dys-
kinesia severity was age at onset, confirming the relevance 
of this variable on the expression of levodopa-induced dys-
kinesia [7].
In a 6-month prospective observational study, the change 
in ICB severity after LCIG was independent of dopamine-
agonist treatment [4]. In our sample, whereas, at the univari-
able analysis, dopamine-agonist dose was associated with 
the diagnosis of ICB, at the multivariable level, the only 
predictors of ICB diagnosis were an age < 75 and severity of 
non-motor symptoms. The association of ICB with younger 
age is well known, whereas, only recently, it has been dem-
onstrated that PD patients with ICB are more likely to pre-
sent specific non-motor symptoms, such as dysautonomia 
[20] or REM behavioral sleep disorder [9].
The main limitations of the present study are small sam-
ple size and the lack of longitudinal assessment of motor 
and non-motor variables. Nevertheless, the comparability 
of quality of life at last follow-up and the lack of association 
between age and quality of life at univariable and multivari-
able analyses support the interpretation that, under LCIG 
treatment, age does not impact on quality of life and motor 
and non-motor severity. Moreover, the strict matching for 
disease duration and LCIG duration of our study cohort is a 
strength, which has minimized the effect of these important 
confounders. Finally, the long follow-up time of our study 
cohort enabled us to have a broad view of the profile of 
adverse events.
In conclusion, our data suggest that advanced PD patients 
that fulfill the general inclusion criteria for LCIG therapy [2] 
are suitable candidates for LCIG treatment independently of 
their age. Prospective studies on LCIG in elderly PD cohorts 
are required to further strengthen this hypothesis and allow 
late elderly PD to receive a treatment which improves their 
quality of life.
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